AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$BENF

CANGANY PETER T JR purchased $20K of BENF

CANGANY PETER T JR purchased 18,868 shares of Beneficient (BENF) at $1.06 on 2026-09-15.

Original reporting
SEC EDGAR · CANGANY PETER T JR
Published Sep 17, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BENF
Neutral
medium confidence
Mentioned
$BENF
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BENFNeutralLow
01

Why it matters

The filing provides a first‑report of a modest insider purchase, offering limited actionable insight.

02

Market read

Routine insider purchase with minimal market impact.

03

What to watch

Potential upcoming clinical data or partnership that prompted the insider buy.

Relevance 4/10Novelty 4/10Timing: filed Sep 17 2026

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$BENFNeutralMedium confidence
Context

Director Cangany Peter T Jr bought 18,868 shares of Beneficient at $1.06 each, increasing his stake to 98,529 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The $20k purchase is a routine insider transaction for a micro‑cap; while it may slightly support the stock, the amount is too small to drive significant price action.

Market effects

Sector

None significant; Beneficient operates in a niche biotech segment with limited sector ripple.

Regional

No broader regional effect.

Global

Negligible.

Counterpoint

What could challenge this read

The purchase could be a signal of upcoming positive news not yet public.

Key entities

  • Company
    Beneficient

    Public biotech issuer (ticker BENF).

  • Insider
    Cangany Peter T Jr

    Director of Beneficient.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BENF insider trading history →

Related articles

SEP 26
$AKAMHighAI 8/10

Akamai's $11.6 Billion Anthropic Cloud Deal, TD SYNNEX's 9.87% Q3 Earnings Plunge Headline Transformative Week for US Stocks

Akamai Technologies (AKAM) announced an $11.6 billion cloud services agreement with Anthropic PBC, lifting shares 14%. The deal includes warrants for Anthropic to acquire up to 5% of Akamai's equity and could expand by $9 billion. The agreement shifts Akamai's focus to AI cloud infrastructure and provides significant revenue visibility.

hdfcsky.com3 min
SEP 23
$BENFMedAI 8/10

Beneficient Announces Strategy to Eliminate HCLP Debt and Heppner Equity Interests

Beneficient (BENF) announced a strategy to eliminate $130M in disputed debt and convert $850M in equity interests held by former CEO Brad Heppner, who was convicted of fraud. The plan aims to resolve all agreements with Heppner before his October sentencing, potentially eliminating substantial debt and unlocking value for shareholders. The company is pursuing a consensual resolution but is prepared to litigate if necessary.

finanznachrichten.de2 min
SEP 23
$BENFMedAI 8/10

Beneficient Announces Strategy to Eliminate HCLP Debt and Heppner Equity Interests

Beneficient (BENF) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Beneficient Announces Strategy to Eliminate HCLP Debt and Heppner Equity Interests DALLAS, September 23, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and r

SEC EDGAR 8-K2 min
AUG 14
$BENFMedAI 8/10

Beneficient Reports First Quarter Fiscal 2027 Results

Beneficient (NASDAQ: BENF) reported fiscal 2027 first-quarter results ended June 30, 2026. The company entered its first collateral management services engagement with a Texas state-chartered bank and closed primary capital commitments totaling over $16 million. Investments with fair value rose to $212.5 million. Operating expenses fell 84.3% to $12.5 million, including a $1.8 million loss-contingency accrual.

finanznachrichten.de6 min